The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition

Kimberly A. Luddy1, Mark Robertson-Tessi2, Narges K. Tafreshi1, Hatem Soliman3 and David L. Morse1*

1 Department of Cancer Imaging and Metabolism, Imaging and Technology Center of Excellence, H. Lee Moffitt Cancer Center, Tampa, FL, USA
2 Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
3 Don and Erika Wallace Comprehensive Breast Program, Center for Women’s Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

INTRODUCTION

Toll-like receptors (TLRs) are a diverse family of pattern recognition receptors expressed by immune cells, intestinal epithelium, and tumor cells. In the homeostatic setting, they help to regulate control over invading pathogens and maintain the epithelial lining of the large and small intestines. Aberrant expression of certain TLRs by tumor cells can induce growth inhibition while others contribute to tumorigenesis and progression. Activation of these TLRs can induce inflammation, tumor cell proliferation, immune evasion, local invasion, and distant metastasis. These TLR-influenced behaviors have similarities with properties observed in leukocytes, suggesting that tumors may be hijacking immune programs to become more aggressive. The concept of epithelial to leucocytic-transition (ELT) is proposed, akin to epithelial to mesenchymal transition, in which tumors develop the ability to activate leucocytic traits otherwise inaccessible to epithelial cells. Understanding the mechanisms of ELT could lead to novel therapeutic strategies for inhibiting tumor metastasis.

Keywords: colorectal cancer, toll-like receptors, epithelial to leucocytic transition, ELT, metastasis, immune evasion, cell plasticity, inflammation

Toll-like receptors (TLRs) are expressed by immune cells, intestinal epithelium, and tumor cells. In the homeostatic setting, they help to regulate control over invading pathogens and maintain the epithelial lining of the large and small intestines. Aberrant expression of certain TLRs by tumor cells can induce growth inhibition while others contribute to tumorigenesis and progression. Activation of these TLRs can induce inflammation, tumor cell proliferation, immune evasion, local invasion, and distant metastasis. These TLR-influenced behaviors have similarities with properties observed in leukocytes, suggesting that tumors may be hijacking immune programs to become more aggressive. The concept of epithelial to leucocytic-transition (ELT) is proposed, akin to epithelial to mesenchymal transition, in which tumors develop the ability to activate leucocytic traits otherwise inaccessible to epithelial cells. Understanding the mechanisms of ELT could lead to novel therapeutic strategies for inhibiting tumor metastasis.
immune cells, commensal bacteria, and IECs is critical for normal digestion and protection against invading pathogens (6). TLRs are key modulators of the immune system of the GI tract. In order to maintain homeostasis and suppress immune responses to commensal bacteria (11), TLR expression and signaling are tightly controlled in this environment (6, 20). However, these controls are disrupted in diseases such as Crohn’s disease and ulcerative colitis, resulting in chronic inflammation (11, 15). Inflammation is linked to cancer through two pathways: extrinsic inflammation induced by non-transformed cells (e.g., invading pathogens or autoimmune disease), and intrinsic inflammation induced by transformed cells (22). In CRC, TLRs are involved in both. Autoimmune diseases cause chronic, smoldering levels of inflammation that predispose individuals into developing CRC (22). Once initiated, tumors can intrinsically activate inflammation through TLR binding by cancer-related DAMPs. Intrinsically and extrinsically induced TLR activation results in tumor-promoting inflammation through NF-κB signaling, leading to expression of the inflammatory cytokines IL-1β, TNFα, and IL-6 (17). This aberrant expression by tumor cells in early carcinogenesis can recruit tumor-promoting immune cells, leading to inflammation and protection from cytotoxic immune cells. Additional data from Kim et al. links mutations in p53 and PTEN to SOCS-mediated activation of IL-6 signaling, leading to intrinsic inflammation (23). Since p53 mutation is a very common event in the natural history of CRC, this is likely a major mechanism of tumor-induced inflammation. Additionally, inflammation can drive genetic and epigenetic changes in cells as well as possible alterations in lineage differentiation programs leading to increased plasticity. This process is also thought to involve NF-κB signaling; however, further studies are needed (22, 24).

**ROLE OF TLRs IN IMMUNE EVASION**

An active immune environment selects for the natural evolution of cancer cells with decreased immunogenic phenotypes. TLR expression in tumors can confer the advantages of both immune evasion and immunosuppression (26). Often pro-inflammatory signals reduce elements of the adaptive immune response. TLR signaling causes a shift in this response from anti-tumor to pro-tumor by affecting the balance toward inflammation and suppression of anti-tumor immunity. Direct TLR activation results in production of immunosuppressive cytokines IL-10 and TGF-β (14, 27), as well as increased expression of immune modulating surface markers PD-L1 and HLA-G (19, 20, 28). These secreted and surface proteins have a tolerizing effect on immune cells. TLR-activated IECs induce the transformation of dendritic cells (DC) into an antigen-specific CD103+ phenotype. These DC promote contact-dependent antigen-specific regulatory T cells (Tregs) that express gut-homing integrins, which further attenuates the anti-tumor immune response (10). Each of these mechanisms are used in the healthy gut to avoid food hypersensitivity or auto-immune diseases. However, dysregulation through abnormal TLR expression can lead to malignant progression.

**ROLE OF TLRs IN INVASION AND METASTASIS**

The most dangerous effect of tumoral TLR signaling is the acquisition of invasive and metastatic tumor phenotypes (29). Ninety percent of patients who succumb to their disease have metastatic lesions (30). TLR expression in tumors is linked to increased grade and distant metastasis (2, 18, 21, 31). The ability of a tumor cell to detach from its epithelial neighbors, break through the basement membrane, and invade nearby tissues is, in part, the result of a long history of aberrant TLR signaling. In CRC, TLR-mediated alterations of the immune system components in the tumor microenvironment can change intracellular signaling (NF-κB), integrin expression (B1 integrin), and motility (29, 32). Activation of TLR4 by LPS in vitro and in vivo induces epithelial to mesenchymal transition (EMT) and invasive phenotypes in certain cell lines (29, 33).

Immune cells are educated by tumor-secreted factors and then actively migrate through the lymphatic vessels and secondary lymphoid organs. These tightly gated organs allow entry and passage to soluble antigens and select immune cell phenotypes, and yet lymph nodes are often the first site of metastasis (34). While it was once thought that tumors cells passively filter into draining lymph nodes, it has recently been shown that tumor cells require chemokine-mediated (CCR7 and CCR8) active transport through the subcapsular sinus epithelium (35, 36). Furthermore, it has been shown that tumor-mediated lymphatic remodeling of peritumoral lymph vessels and draining lymph nodes facilitates metastasis (37–40). TLRs may play a role in this metastatic process, since TLR activation leads to increased expression of CCR7 and CCR8 (41), which are key molecules expressed by leukocytes to access lymphatics (35, 42). This suggests that the tumor cells can harness existing leukocytic mechanisms to begin the metastatic cascade through the lymph nodes.

Lymphocytes typically traffic throughout the body to sites of inflammation, using chemokines, selectins, and integrins as
Many metastatic tumors have been shown to use the expression of these same molecules to colonize distal sites (44, 45). As an example, CXCR4 is a well-characterized bone marrow homing receptor expressed by T cells (46); research has found that both prostate cancers (47) and breast cancers (48) that metastasize to the bone commonly express CXCR4. CRC typically metastasizes to the liver or lung. Aberrant expression of CXCR3, CXCR4/CXCR7, and CCR6 are commonly found in liver and lung metastasis of colon cancer (49–55). Ligands for these receptors (CXCL19, SDF-1, and CCL20, respectively) are highly expressed in the liver and lungs of metastatic CRC patients (53, 56–58). Local inflammation in these organs induces ligand expression and preferential organ metastasis is determined by their expression (59, 60).

Alteration in integrin signaling is another metastatic mechanism induced by TLR signaling (26). Integrin signaling is used in healthy systems to aid immune cell trafficking (61). Aberrant expression of these integrins via TLR signaling allows circulating tumor cells to respond to the same trafficking mechanisms that an immune cell uses to migrate to distal sites (2, 32, 62, 63). Similar examples have been shown with integrins in colon cancer (64), breast cancer (65), and melanoma (66). These expressed surface markers are a natural part of the lymphocytic trafficking system, and their expression on tumor cells could be evidence that tumor cells use leucocytic trafficking mechanisms to metastasize.

**EPITHELIAL TO LEUCOCYTIC TRANSITION**

The co-opting of immune cell signaling and migration mechanisms by tumor cells is well documented, with many citing the plasticity of tumor cells and inappropriate gene expression as the underlying cause of treatment resistance and metastatic growth (13, 67–70). Pressures from cytotoxic immune cells, abundant inflammation, cytotoxic drugs, and targeted therapies push tumor cells into plastic states where they may begin to access programed mechanisms outside of their usual function (68). The survivors of these selection pressures are adaptive and dynamic cells, many of which express patterns of proteins found in normal other cell types (70, 71). These protein expression patterns have been used to define and detect EMT, for example. An increasing number of publications suggest that although EMT is important in locally invasive and invasive capability of tumor cells, but do not necessarily explain immunoevasion, lymphatic access, and metastatic spread (35, 69, 72). We therefore propose the parallel concept of epithelial to leucocytic transition (ELT) as a framework, akin to EMT, with which to understand the metastatic properties of cancer cells. Figure 1 illustrates the primary properties gained by tumor cells that undergo ELT. We consider ELT to be a partial transition in which epithelial cells retain their epithelial origin while at the same time acquiring a set of leucocytic traits. Tumor cells co-opt many mechanisms of the immune system for their own transport and these mechanisms are activated by proteins typically reserved for sense, immunosuppression, migration through tissue, intra- and extravasation through lymph and blood vessels, rapid proliferation, altered metabolism, and homing to specific tissues are key hallmarks of both cancer and the immune system.

Pathogenic EMT has its roots in normal embryogenesis. In cancer, this transition results in epithelial cells with a range of mesenchymal protein expression. These alterations increase motility and invasive capability of tumor cells, but do not necessarily explain immunoevasion, lymphatic access, and metastatic spread (35, 69, 72). We therefore propose the parallel concept of epithelial to leucocytic transition (ELT) as a framework, akin to EMT, with which to understand the metastatic properties of cancer cells. Figure 1 illustrates the primary properties gained by tumor cells that undergo ELT. We consider ELT to be a partial transition in which epithelial cells retain their epithelial origin while at the same time acquiring a set of leucocytic traits. Tumor cells co-opt many mechanisms of the immune system for their own transport and these mechanisms are activated by proteins typically reserved for
the immune response. A leucocytic tumor cell expresses proteins that allow for regulation and co-opting of the immune system such as PD-L1, CD80/86, TLR, TGF-β, CCL4, and CCL5 (80) (Figure 1, properties 1 and 4). Additional leucocytic proteins (CXCR4, CCR7, CCR8) facilitate invasion and proliferation within lymph nodes (Figure 1, property 2) (35, 42, 81). Processes critical to survival in circulation, homing to tissue specific sites, and successful extravasation are mediated by E/P-selectin, L-selectin ligands, α4β1, ICAM-1, and VCAM-1 (61, 73, 82–86) (Figure 1, property 3). By harnessing mechanisms usually reserved for immune cells, tumor cells gain the ability to become more aggressive. In the case of TLRs, a cycle of overexpression and resulting inflammation promotes plasticity of the epithelial phenotype. This plasticity permits tumor cells to undergo ELT, accessing immune programs that facilitate invasion and metastasis of the cancer. ELT, as with other plastic states, is likely transient, making the evaluation of these phenotypes a significant challenge. TLR-mediated evolution of CRC may be a good model to study how ELT occurs, since TLRs are primarily seen in immune cells and the overexpression of TLRs appears to promote an immune-like phenotype in CRC.

Understanding the acquisition of the leucocytic phenotype could reveal key targets that would prevent CRC cells from accessing dangerous invasion and trafficking mechanisms through a plastic transition. Simply antagonizing TLRs and associated molecules may not be enough, since resistance is likely to develop. However, if the mechanisms of plasticity induced by TLRs are understood, new targets may be developed to inhibit ELT.

It is important to note that the key functional activities of immune cells, specifically the CD8 cytotoxic T-cell phenotype and the antibody producing activated B-cell phenotypes, have not yet been described in tumor cells. However, other cytotoxic mechanisms utilized by immune cells have been seen in normal and neoplastic epithelial cells. Tumor cell cannibalism, resembling phagocytosis, of neighboring apoptotic cells as well as infiltrating immune cells has been seen during times of metabolic stress (87). During mammary involution, epithelial-derived FAS plays a role in FASL-mediated cell death (88). Tumor cells can secrete FAS, TNFα, and TGFβ, proteins capable of promoting and inhibiting epithelial cell death (89–91). Additionally, PD-L1 proteins on tumor cells result in T-cell anergy and apoptosis (92, 93). Although, none of these represent the antigen-specific killing of the adaptive immune system, it is our opinion that further exploration is needed to determine how far epithelial cells can evolve to obtain immune-like processes and that cell killing can not yet be included or excluded from that hypothesis.

CONCLUSION

Originally, lymphatic dissemination into draining lymph nodes was considered a clear indicator of prognosis and was attributed to tumor chronology based on the correlation of tumor volumes and lymph node metastasis. However, later larger studies often showed conflicting results. Jatoi et al. (94, 95) and others attributed these differences to the tumor phenotype as opposed to a simple passage of time. This means that tumor phenotypes can exist on a continuum from slow growing with late lymph node metastasis to aggressive early disseminators much more capable of exiting the lymph node and establishment at distant sites (94, 95). While lymph node positivity is a useful tool for treatment decisions understanding the complexities of these aggressive phenotypes is key to halting the lymphatic dissemination of cancer.

Many host parameters contribute to natural progression of tumor metastasis and the extent of tumor cell plasticity is not yet fully appreciated. In an opinion article on tumor and immune cell plasticity, Holzel et al. (68) recognize the similarity between cancer cells and immune cells by linking inflammation and evolutionary pressures to the creation of plastic phenotypes. We think that this idea needs to be taken further to include a plastic transition to an immune-like phenotype, i.e., ELT, in the context tumor development, invasion, metastasis, and resistance to therapies. Specifically in CRC, the tumor cells acquire many hallmarks of the immune system, and this transition is intimately tied to aberrant TLR expression. By considering TLR expression in the context of ELT, the transition to a migratory immune-like and therefore metastatic phenotype might be better understood, and therefore, lead to better therapeutic strategies.

REFERENCES

1. Rahman AH, Taylor DK, Turka LA. The contribution of direct TLR signaling to T cell responses. Immuno Res (2009) 45(1):25–36. doi:10.1007/s12302-009-8113-x
2. Lu Q, Ding H, Li W. Role of toll-like receptors in microbiota-associated gastrointestinal cancer metastasis. Cancer Res Ther (2015) 9(6 Suppl):S142–9. doi:10.4103/0973-1482.132509
3. Du T, Zhou ZG, You S, Huang G, Lin J, Yang L, et al. Modulation of monocyte hyperresponsiveness to TLR ligands by L25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Res Clin Pract (2009) 83(2):208–14. doi:10.1016/j.diabres.2008.09.046
4. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol (2013) 10(2):103–6. doi:10.1038/cmi.2012.61
5. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4(7):499–511. doi:10.1038/nri1391
6. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol (2010) 10(2):131–44. doi:10.1038/nri2707
7. Zarember KA, Godowski PJ. Tissue expression of human toll-like receptors and their ligands in leukocytes in response to microbes, their products, and cytokines. J Immunol (2002) 168(2):554–61. doi:10.4049/jimmunol.168.2.554
8. Applegate SE, Wallin RP, Ljunggren HG. Variable expression of toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol (2002) 168(2):554–61. doi:10.4049/jimmunol.168.2.554
9. Takezaka S, McCormick S, Safonova E, Xing Z, Gauldie J. Influence of the tissue microenvironment on toll-like receptor expression by CD11c+ antigen-presenting cells isolated from mucosal tissues. Clin Vaccine Immunol (2009) 16(11):1615–23. doi:10.1128/CVI.00216-09
10. de Kivit S, Tobin MC, Forsyth CB, Roshavarian A, Landay AL. Regulation of intestinal immune responses through TLR activation: implications for pro- and prebiotics. Front Immunol (2014) 5:60. doi:10.3389/fimmu.2014.00660
11. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 16(9):1583–97. doi:10.1002/ibd.21282
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74. doi:10.1016/j.cell.2011.02.013
13. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):867–71. doi:10.1038/nature01222
14. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al. Molecular pathways: toll-like receptors in the tumor microenvironment – poor prognosis or new therapeutic opportunity. Clin Cancer Res (2013) 19(6):1340–6. doi:10.1158/1078-0432.CCR-12-0408
15. Satoh T, Goto E, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron (2009) 2(1 Suppl):205–14. doi:10.1007/s12307-009-0022-y
34. Alitalo K. The lymphatic vasculature in disease. J Immunother (2010) 33(6):342–9. doi:10.1097/CJI.0b013e3181d95e56

35. Frizelle FA, Frizelle FH. The role of chemokines in the pathogenesis of colorectal cancer. J Pathol (2009) 218(1):94–104. doi:10.1002/path.2507

36. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. J Exp Metastasis (2008) 25(4):345–56. doi:10.1007/s10585-007-9097-9

37. Fukumura D, Duda DG, Gunn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 17(3):206–25. doi:10.1111/j.1547-8179.2010.00259.x

38. Ji RC. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol (2009) 24(3):377–84.

39. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci (2008) 1131:225–34. doi:10.1196/annals.1413.020

40. Wu X, Yamauchi T, Kikuchi T, Kondo H, Kato S, Nakajima K, Takahashi T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 94(11):819–25. doi:10.1093/jnci/94.11.819

41. Monteleone I, Platt AM, Jaensson E, Agace WW, Monat AW. IL-10-dependent partial refractoriness to toll-like receptor stimulation modulates gut mucosal dendritic cell function. Eur J Immunol (2008) 38(6):1533–47. doi:10.1002/eji.200737909

42. Fusi A, Liu Z, Kummerlen V, Nonnenmacher A, Jeske J, Kelbhold U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med (2012) 10:52. doi:10.1186/1479-5876-10-52

43. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Paganos KA, Guo RF, et al. Role of Cia in multiguan failure during sepsis. J Immunol (2001) 166(2):1193–9. doi:10.4049/jimmunol.166.2.1193

44. Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of metastasis. Cell Signal (2009) 21(5):665–74. doi:10.1016/j.cellsig.2009.01.006

45. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol (2010) 20(3):169–77. doi:10.1016/j.semcancer.2010.04.005

46. Alberda WJ, Dassen HP, Dwarkasing RS, Willemse F, van der Ploeg AE, de Wilt JH, et al. Prediction of tumor stage and lymph node involvement with dynamic contrast-enhanced MRI after chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis (2013) 28(4):573–80. doi:10.1007/s00384-012-1617-6

47. Toischmann RS, Cooper C, Keller KT, Pienta KA, Taichman NS, McCaulley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 62(6):1832–7.

48. Jain S, Sharma P, Mukherjee A, Bal C, Kumar R. “Witch’s milk” and 99mTc-percetchnate uptake in neonatal breast tissue: an uncommon but not unexpected finding. Clin Nucl Med (2013) 38(7):586–7. doi:10.1097/RLU.0b013e318292aaba

49. Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer (2013) 132(2):276–87. doi:10.1002/ijc.27670

50. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene (2007) 26(31):4679–88. doi:10.1038/sj.onc.1210267

51. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 23(12):2744–53. doi:10.1200/JCO.2005.07.078

52. Ghadirzadeh F, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, et al. Role of CXCR4 expression in colorectal cancer metastasis. J Clin Oncol (2005) 23(2):276–87. doi:10.1200/JCO.2004.19.1822

53. Rubic C, Oliveira-Vempt K, Wagner M, Tilton B, Rau B, et al. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol (2006) 27(3):166–74. doi:10.1159/000092777

54. Rubic C, Oliveira-Frnick V, Rau B, Schilling M, Wagner M, Chemokine receptor CCR6 expression in colorectal liver metastasis. J Clin Oncol (2006) 24(32):5173–4; author reply 4. doi:10.1200/JCO.2006.07.9095

55. Rubic C, Kollmar O, Frick VO, Wagner M, Britter B, Graber S, et al. Differen- tial CCR3 receptor expression in colorectal carcinomas. Scand J Immunol (2008) 68(6):635–44. doi:10.1111/j.1365-3083.2008.02163.x

56. Iwasa S, Yanagawa T, Fan J, Katoh R. Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metas- tasis. Anticancer Res (2009) 29(11):4751–8.

57. Matsuura R, Kubo H, Hisamori S, Okoshi K, Takagi H, Kida H, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol (2009) 16(9):2645–53. doi:10.1240/jso/10345-009-0599-x

Ludy et al. Toll-like receptors in colon cancer

www.frontiersin.org October 2014 | Volume 5 | Article 429 | 5
81. Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol (2012) 18(11):1249–56. doi:10.3748/wjg.v18.i11.1249

82. Kitamura J, Nagawa H, Tsuno N, Osada T, Hatano K, Sunami E, et al. Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow. Br J Cancer (1999) 80(12):1927–34. doi:10.1038/sj.bjc.6690622

83. Roy J, Audette M, Tremblay MJ. Intercellular adhesion molecule-1 (ICAM-1) gene expression in human T cells is regulated by phosphotyrosyl phosphatase activity. Involvement of NF-kappaB, Ets, and palindromic interferon-gamma-responsive element-binding sites. J Biol Chem (2001) 276(18):14553–61. doi:10.1074/jbc.M005067200

84. Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol (2003) 9(7):1409–14.

85. Burdick MM, Chue JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem (2006) 281(10):8389–95. doi:10.1074/jbc.M513617200

86. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol (1993) 4(2):219–29.

87. Caruso RA, Fedele F, Finocchiaro G, Arena G, Venuti A. Neutrophil-tumor cell phagocytosis (cannibalism) in human tumors: an update and literature review. Exp Oncol (2012) 34(3):306–11.

88. Song J, Sapi E, Brown W, Nilsen J, Tarrato K, Kacimini BM, et al. Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest (2000) 106(1):1209–20. doi:10.1172/JCI10411

89. Mullauer L, Mosberger I, Grusch M, Radas M, Chott A. Fas ligand is expressed in normal epithelial cells and is frequently up-regulated in breast cancer. J Pathol (2000) 191(1):20–30. doi:10.1002/(SICI)1096-9896(200001)191:1<20::AID-PATH197>3.0.CO;2-S

90. S spriggs DR, Imamura K, Rodriguez C, Sariban E, Kufe DW. Tumor necrosis factor expression in human epithelial tumor cell lines. J Cancer Res (1988) 81(2):455–60. doi:10.1097/00019606-198802000-00005

91. Humbert L, Lebrun JF. TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. Cell Signal (2013) 25(2):490–500. doi:10.1016/j.cellsig.2012.10.011

92. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang YJ, et al. PD-1 and PD-1 ligand upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer (2011) 128(4):887–96. doi:10.1002/ijc.25937

93. Koscielny S, Le MG, Tubiana M. The natural history of human breast cancer. The relationship between involvement of auxiliary lymph nodes and the initiation of distant metastases. Br J Cancer (1989) 59(3):755–82. doi:10.1038/bjc.1989.162

94. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of auxiliary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 17(8):2334–40.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 22 April 2014; accepted: 22 August 2014; published online: 20 October 2014. Citation: Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H and Morse DL (2014) The role of toll-like receptors in colorectal cancer progression: evidence for epithelial-to-leukocyte transition. Front. Immunol. 5:429. doi:10.3389/fimmu.2014.00429

This article was submitted to Tumor Immunology, a section of the Journal Frontiers in Immunology. Copyright © 2014 Luddy, Robertson-Tessi, Tafreshi, Soliman and Morse. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.